KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Finished Goods (2018 - 2025)

Twist Bioscience (TWST) has disclosed Finished Goods for 6 consecutive years, with $4.8 million as the latest value for Q2 2023.

  • On a quarterly basis, Finished Goods fell 41.13% to $4.8 million in Q2 2023 year-over-year; TTM through Jun 2023 was $4.8 million, a 41.13% decrease, with the full-year FY2022 number at $7.7 million, down 6.49% from a year prior.
  • Finished Goods was $4.8 million for Q2 2023 at Twist Bioscience, down from $5.3 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $9.6 million in Q1 2022 to a low of $425000.0 in Q1 2019.
  • A 5-year average of $4.8 million and a median of $5.1 million in 2023 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: skyrocketed 693.89% in 2021, then tumbled 44.72% in 2023.
  • Twist Bioscience's Finished Goods stood at $1.3 million in 2019, then soared by 38.88% to $1.8 million in 2020, then soared by 282.35% to $6.8 million in 2021, then increased by 9.9% to $7.4 million in 2022, then crashed by 34.76% to $4.8 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Finished Goods are $4.8 million (Q2 2023), $5.3 million (Q1 2023), and $7.4 million (Q4 2022).